XML 55 R42.htm IDEA: XBRL DOCUMENT
v3.21.2

Revenue - Business Revenue (Details) - USD ($) | 3 Months Ended | 9 Months Ended
--- | --- | ---
Jun. 26, 2021 | Jun. 27, 2020 | Jun. 26, 2021 | Jun. 27, 2020
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | $ 1,168,300,000 | $ 822,900,000 | $ 4,315,700,000 | $ 2,429,500,000
Contract with Customer, Liability, Revenue Recognized | 20,100,000 | 18,000,000.0 | 100,900,000 | 95,500,000
United States |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 749,900,000 | 660,800,000 | 2,951,700,000 | 1,868,500,000
International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 418,400,000 | 162,100,000 | 1,364,000,000.0 | 561,000,000.0
Diagnostics |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 665,500,000 | 532,200,000 | 2,858,200,000 | 1,163,200,000
Diagnostics | United States |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 357,200,000 | 439,100,000 | 1,825,800,000 | 909,100,000
Diagnostics | International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 308,300,000 | 93,100,000 | 1,032,400,000 | 254,100,000
Diagnostics | Cytology & Perinatal |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 115,900,000 | 64,100,000 | 357,900,000 | 298,700,000
Diagnostics | Cytology & Perinatal | United States |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 73,900,000 | 40,300,000 | 230,800,000 | 191,100,000
Diagnostics | Cytology & Perinatal | International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 42,000,000.0 | 23,800,000 | 127,100,000 | 107,600,000
Diagnostics | Molecular Diagnostics |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 536,400,000 | 460,300,000 | 2,467,000,000.0 | 829,500,000
Diagnostics | Molecular Diagnostics | United States |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 270,100,000 | 391,000,000.0 | 1,561,700,000 | 683,000,000.0
Diagnostics | Molecular Diagnostics | International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 266,300,000 | 69,300,000 | 905,300,000 | 146,500,000
Diagnostics | Blood Screening |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 13,200,000 | 7,800,000 | 33,300,000 | 35,000,000.0
Diagnostics | Blood Screening | United States |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 13,200,000 | 7,800,000 | 33,300,000 | 35,000,000.0
Diagnostics | Blood Screening | International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 0 | 0 | 0 | 0
Breast Health |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 349,000,000.0 | 224,000,000.0 | 1,018,000,000.0 | 862,800,000
Breast Health | United States |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 273,200,000 | 170,600,000 | 784,400,000 | 661,500,000
Breast Health | International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 75,800,000 | 53,400,000 | 233,600,000 | 201,300,000
Breast Health | Breast Imaging |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 280,300,000 | 193,200,000 | 817,800,000 | 718,200,000
Breast Health | Breast Imaging | United States |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 218,400,000 | 145,600,000 | 619,500,000 | 541,100,000
Breast Health | Breast Imaging | International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 61,900,000 | 47,600,000 | 198,300,000 | 177,100,000
Breast Health | Interventional Breast Solutions |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 68,700,000 | 30,800,000 | 200,200,000 | 144,600,000
Breast Health | Interventional Breast Solutions | United States |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 54,800,000 | 25,000,000.0 | 164,900,000 | 120,400,000
Breast Health | Interventional Breast Solutions | International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 13,900,000 | 5,800,000 | 35,300,000 | 24,200,000
GYN Surgical |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 127,900,000 | 51,500,000 | 366,200,000 | 275,900,000
GYN Surgical | United States |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 103,900,000 | 42,100,000 | 296,800,000 | 227,600,000
GYN Surgical | International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 24,000,000.0 | 9,400,000 | 69,400,000 | 48,300,000
Medical Aesthetics |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 0 | 0 | 0 | 65,300,000
Medical Aesthetics | United States |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues |  |  | 0 | 30,900,000
Medical Aesthetics | International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues |  |  | 0 | 34,400,000
Skeletal Health |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 25,900,000 | 15,200,000 | 73,300,000 | 62,300,000
Skeletal Health | United States |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 15,600,000 | 9,000,000.0 | 44,700,000 | 39,400,000
Skeletal Health | International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | $ 10,300,000 | $ 6,200,000 | $ 28,600,000 | $ 22,900,000

X
- Definition Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045 + Details
Name: | us-gaap_ContractWithCustomerLiabilityRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_DisaggregationOfRevenueLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 28 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 235 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=holx_InternationalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=holx_DiagnosticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=holx_CytologyPerinatalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=holx_MolecularDiagnosticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=holx_BloodScreeningMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=holx_BreastHealthMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=holx_BreastImagingMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=holx_InterventionalBreastSolutionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=holx_GynSurgicalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=holx_MedicalAestheticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=holx_SkeletalHealthMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |